Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,247,241
  • Shares Outstanding, K 111,490
  • Annual Sales, $ 74,910 K
  • Annual Income, $ -761,500 K
  • 60-Month Beta 2.44
  • Price/Sales 74.89
  • Price/Cash Flow N/A
  • Price/Book 8.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -2.21
  • Number of Estimates 7
  • High Estimate -1.92
  • Low Estimate -2.39
  • Prior Year -2.09
  • Growth Rate Est. (year over year) -5.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.53 +6.54%
on 01/14/20
122.42 -2.94%
on 01/15/20
+2.27 (+1.95%)
since 12/17/19
3-Month
81.34 +46.08%
on 10/18/19
125.72 -5.49%
on 12/06/19
+36.94 (+45.11%)
since 10/17/19
52-Week
65.81 +80.55%
on 05/20/19
125.72 -5.49%
on 12/06/19
+38.14 (+47.27%)
since 01/17/19

Most Recent Stories

More News
New Study Indicates 'Helper' Cells May Kill Cancerous Tumors

USA News Group - A new study out suggests that T cells are a subset of lymphocytes (white blood cells), which play a key role in the body's immune response. This new information could prove to be a key...

ALNY : 118.82 (-0.44%)
ONCY : 3.10 (-2.52%)
ONC.TO : 4.06 (+0.25%)
BMY : 66.72 (-0.09%)
AEMD : 2.06 (-25.36%)
Alnylam Pharmace Set to Possibly Rebound After Yesterday's Selloff of 3.97%

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $112.48 to a high of $118.49. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of...

ALNY : 118.82 (-0.44%)
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

NVS : 95.93 (+0.87%)
ALNY : 118.82 (-0.44%)
ALXN : 113.27 (+0.68%)
CUE : 15.40 (-8.17%)
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

--- As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO and Over 1,000 Total Patients Worldwide Being Treated with Patisiran -

ALNY : 118.82 (-0.44%)
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

--- Lumasiran Granted Pediatric Rare Disease Designation by FDA for the Treatment of PH1 -

ALNY : 118.82 (-0.44%)
Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference...

JPM : 138.20 (+0.69%)
ALNY : 118.82 (-0.44%)
Alnylam Stock Up More Than 61% YTD on Pipeline Progress

Shares of Alnylam (ALNY) rise on significant pipeline progress.

ALNY : 118.82 (-0.44%)
REGN : 385.94 (+0.10%)
ALKS : 19.24 (-3.75%)
INVA : 14.43 (-0.55%)
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

Smart Beta ETF report for EUSA

EUSA : 65.58 (+0.19%)
SPLK : 157.96 (-1.47%)
BMY : 66.72 (-0.09%)
VTI : 168.76 (+0.25%)
ITOT : 74.93 (+0.20%)
ALNY : 118.82 (-0.44%)
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study

Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.

MDCO : 84.90 (-0.07%)
REGN : 385.94 (+0.10%)
ALKS : 19.24 (-3.75%)
ALNY : 118.82 (-0.44%)
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

--a^' Alnylam Intends to File New Drug Application (NDA) and Marketing Authorisation Application (MAA) in Early 2020 -

ALNY : 118.82 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 121.45
1st Resistance Point 120.13
Last Price 118.82
1st Support Level 116.83
2nd Support Level 114.85

See More

52-Week High 125.72
Last Price 118.82
Fibonacci 61.8% 102.83
Fibonacci 50% 95.76
Fibonacci 38.2% 88.70
52-Week Low 65.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar